Search company, investor...

Affimed Therapeutics

affimed.com

Founded Year

2000

Stage

IPO | IPO

Total Raised

$116.41M

Date of IPO

9/12/2014

Market Cap

0.31B

Stock Price

2.01

Revenue

$0000 

About Affimed Therapeutics

Affimed Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

Headquarters Location

Technologiepark Im Neuenheimer Feld 582

Heidelberg, D-69120,

Germany

49-(0)6221-65307-0

Missing: Affimed Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Affimed Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Affimed Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Affimed Therapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Affimed Therapeutics Patents

Affimed Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/2/2020

11/29/2022

Tyrosine kinase receptors, Experimental cancer drugs, Clusters of differentiation, Monoclonal antibodies, Receptor tyrosine kinase inhibitors

Grant

Application Date

9/2/2020

Grant Date

11/29/2022

Title

Related Topics

Tyrosine kinase receptors, Experimental cancer drugs, Clusters of differentiation, Monoclonal antibodies, Receptor tyrosine kinase inhibitors

Status

Grant

Latest Affimed Therapeutics News

Affimed (AFMD) Stock: Why The Price Increased Today

Mar 31, 2022

The stock price of Affimed NV (NASDAQ: AFMD) increased by over 1% pre-market today. This is why. The stock price of Affimed NV (NASDAQ: AFMD) increased by over 1% pre-market today. Investors are responding positively to a bullish research report. Piper Sandler analyst Do Kim initiated coverage on Affimed Therapeutics with an “Overweight” rating. And Kim assigned the company a price target of $7, which imputes a 57% upside. “We believe Affimed’s bispecific ICE molecules can activate innate immune cells to kill tumors through CD16A and cancer antigen targeting. In addition, we believe the combination of ICE therapies and NK cells enable CAR-like efficacy, but without CAR-T-associated CRS and neurotoxicity AEs,” wrote Kim in a research note. “We expect AFM13 REDIRECT Phase 2 data in 2H22 to support accelerated filing in PTCL and launch of Affimed’s first approved therapy. We believe MDACC-sponsored Phase 1/2a data confirm the enhanced potency of precomplexed AFM13+cbNK cells, while maintaining a benign safety profile. We believe combination with NK cells provide the best chance for AFM24 to have transformative efficacy in EGFR+ solid tumors, potentially expanding the $9.0B market for current EGFR therapies. We believe AFM24 provides the most upside, as Phase 1/2 data updates in 2H22 could further de-risk the large EGFR cancer opportunity.” Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Affimed Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Affimed Therapeutics Rank

Affimed Therapeutics Frequently Asked Questions (FAQ)

  • When was Affimed Therapeutics founded?

    Affimed Therapeutics was founded in 2000.

  • Where is Affimed Therapeutics's headquarters?

    Affimed Therapeutics's headquarters is located at Technologiepark, Heidelberg.

  • What is Affimed Therapeutics's latest funding round?

    Affimed Therapeutics's latest funding round is IPO.

  • How much did Affimed Therapeutics raise?

    Affimed Therapeutics raised a total of $116.41M.

  • Who are the investors of Affimed Therapeutics?

    Investors of Affimed Therapeutics include OrbiMed Advisors, EQT Life Sciences, BioMedPartners, Novo Nordisk, Aeris Capital and 5 more.

  • Who are Affimed Therapeutics's competitors?

    Competitors of Affimed Therapeutics include Xencor, Merus, Scancell, Symphogen, OncoMed Pharmaceuticals and 9 more.

Compare Affimed Therapeutics to Competitors

A
ApoLife

ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and antibodies and subunit vaccines through its Twin Cassette yeast system. ApoLife employs Bakers yeast (S.cerevisiae) which has been used for manufacturing several FDA approved therapeutic products thus giving ApoLife a competitive regulatory advantage over companies using other yeast systems. ApoLife's platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process.ApoLife uses its technology to develop anticancer antibodies and immunotoxins with collaborating partners.As a licensing partner, ApoLife has vectors, yeast strains, and production process available for antibody and biogeneric product development.

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

ImmunoReagents Logo
ImmunoReagents

ImmunoReagents is a cGMP manufacturing facility for antibodies used in the In Vitro Diagnostic Industry, which specializes in polyclonal antibodies to human proteins and secondary antibodies.

I
IMED

IMED AB develops human monoclonal antibodies (MABs) that can induce or block natural cell death (apoptosis). There are many medical uses for these antibodies including HIV, cancer and transplantation. The company intends to license its products to large pharmaceutical companies.

PharmAthene Logo
PharmAthene

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.

M
ModiQuest

ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.